Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts

Insulin receptor substrates (IRS-1 and IRS-2) are essential for intracellular signaling by insulin and insulin-like growth factor-I (IGF-I), anabolic regulators of bone metabolism. Although mice lacking the IRS-2 gene (IRS-2 −/− mice) developed normally, they exhibited osteopenia with decreased bone formation and increased bone resorption. Cultured IRS-2 − / − osteoblasts showed reduced differentiation and matrix synthesis compared with wild-type osteoblasts. However, they showed increased receptor activator of nuclear factor κB ligand (RANKL) expression and osteoclastogenesis in the coculture with bone marrow cells, which were restored by reintroduction of IRS-2 using an adenovirus vector. Although IRS-2 was expressed and phosphorylated by insulin and IGF-I in both osteoblasts and osteoclastic cells, cultures in the absence of osteoblasts revealed that intrinsic IRS-2 signaling in osteoclastic cells was not important for their differentiation, function, or survival. It is concluded that IRS-2 deficiency in osteoblasts causes osteopenia through impaired anabolic function and enhanced supporting ability of osteoclastogenesis. We propose that IRS-2 is needed to maintain the predominance of bone formation over bone resorption, whereas IRS-1 maintains bone turnover, as we previously reported; the integration of these two signalings causes a potent bone anabolic action by insulin and IGF-I.

[1]  I. Deary,et al.  Insulin resistance , 1996 .

[2]  L. Formigli,et al.  Characterization and function of the receptor for IGF-I in human preosteoclastic cells. , 1996, Bone.

[3]  M. White,et al.  IRS proteins and beta-cell function. , 2001, Diabetes.

[4]  J. Wozney,et al.  Bone morphogenetic protein 2 transiently enhances expression of a gene, Id (inhibitor of differentiation), encoding a helix-loop-helix molecule in osteoblast-like cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Rao,et al.  Bone Mineral Density in Diabetes , 1997, Diabetes Care.

[6]  John H. White,et al.  Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3–dependent signal transduction by phosphorylating human retinoid X receptor α , 1999 .

[7]  M. White,et al.  [Letters to nature] , 1975, Nature.

[8]  E. Canalis.  Insulin like growth factors and the local regulation of bone formation. , 1992, Bone.

[9]  L. Donahue,et al.  Circulating and skeletal insulin-like growth factor-I (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities. , 1997, Bone.

[10]  I. Ohnishi,et al.  Insulin Secretory Response Is Positively Associated with the Extent of Ossification of the Posterior Longitudinal Ligament of the Spine , 2001, The Journal of bone and joint surgery. American volume.

[11]  M. Horton,et al.  Interleukin-4 and interleukin-13: bidirectional effects on human osteoclast formation. , 2001, Bone.

[12]  T. Yagi,et al.  Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1 , 1994, Nature.

[13]  M. White,et al.  The IRS-signalling system: A network of docking proteins that mediate insulin action , 1998, Molecular and Cellular Biochemistry.

[14]  G. Sesti,et al.  Defects of the insulin receptor substrate (IRS) system in human metabolic disorders , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  M. Odawara,et al.  Activated Protein C Resistance and Japanese NIDDM Patients With Coronary Heart Disease , 1997, Diabetes Care.

[16]  G. Lienhard,et al.  A Novel 160-kDa Phosphotyrosine Protein in Insulin-treated Embryonic Kidney Cells Is a New Member of the Insulin Receptor Substrate Family* , 1997, The Journal of Biological Chemistry.

[17]  M. Kumegawa,et al.  Insulin-like growth factor-I supports formation and activation of osteoclasts. , 1992, Endocrinology.

[18]  C. Kao,et al.  Bone mineral density in patients with noninsulin-dependent diabetes mellitus by dual photon absorptiometry. , 1993, Nuclear medicine communications.

[19]  T. Martin,et al.  Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction , 2022 .

[20]  Z. Laron,et al.  Patients with Laron Syndrome Have Osteopenia/Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  G. Karsenty,et al.  Regulation of bone formation and vision by LRP5. , 2002, The New England journal of medicine.

[22]  A. Hofman,et al.  Bone Density in Non-Insulin-Dependent Diabetes Mellitus: The Rotterdam Study , 1995, Annals of Internal Medicine.

[23]  S. Teitelbaum,et al.  Correction of abnormal bone and mineral metabolism in chronic streptozotocin-induced diabetes mellitus in the rat by insulin therapy. , 1981, Endocrinology.

[24]  Y. Terauchi,et al.  Increased Expression of the Sterol Regulatory Element-binding Protein-1 Gene in Insulin Receptor Substrate-2−/−Mouse Liver* , 2001, The Journal of Biological Chemistry.

[25]  M. White,et al.  IRS proteins and β-cell function , 2001 .

[26]  S. Aizawa,et al.  Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. , 2000, Diabetes.

[27]  G. Karsenty.  Minireview: transcriptional control of osteoblast differentiation. , 2001, Endocrinology.

[28]  K. Ikeda,et al.  Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  M. Laakso,et al.  New amino acid substitutions in the IRS-2 gene in Finnish and Chinese subjects with late-onset type 2 diabetes. , 2001, Diabetes.

[30]  E. Canalis.  Insulin-like growth factors and osteoporosis. , 1997, Bone.

[31]  C. Kahn,et al.  Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene , 1994, Nature.

[32]  T. Sato,et al.  Identification and Characterization of the Insulin‐like Growth Factor I Receptor in Mature Rabbit Osteoclasts , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  N. Sonenberg,et al.  Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice , 1996, Molecular and cellular biology.

[34]  J. Zamorano,et al.  A Role for the Insulin-Interleukin (IL)-4 Receptor Motif of the IL-4 Receptor α-Chain in Regulating Activation of the Insulin Receptor Substrate 2 and Signal Transducer and Activator of Transcription 6 Pathways , 1998, The Journal of Biological Chemistry.

[35]  M. White,et al.  Stat6 and IRS-2 Cooperate in Interleukin 4 (IL-4)-Induced Proliferation and Differentiation but Are Dispensable for IL-4-Dependent Rescue from Apoptosis , 2002, Molecular and Cellular Biology.

[36]  N. Udagawa,et al.  Insulin receptor expression in primary and cultured osteoclast-like cells. , 1998, Bone.

[37]  C. Kahn,et al.  Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells , 1997, Molecular and cellular biology.

[38]  Y. Azuma,et al.  Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. , 2000, The Journal of clinical investigation.

[39]  C. Rosen.  Growth hormone, insulin‐like growth factors, and the senescent skeleton: Ponce de Leon's fountain revisited? , 1994, Journal of cellular biochemistry.

[40]  NEW amino acid. , 1953, Nutrition reviews.

[41]  G. Lienhard,et al.  The 60-kDa Phosphotyrosine Protein in Insulin-treated Adipocytes Is a New Member of the Insulin Receptor Substrate Family* , 1997, The Journal of Biological Chemistry.

[42]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.

[43]  Y. Nagai,et al.  Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells , 2000, Journal of cellular physiology.

[44]  G. Shulman,et al.  Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.

[45]  J. Reynolds,et al.  Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. , 1995, Endocrinology.

[46]  C. Kahn,et al.  Erratum: Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene (Nature (1994) 372 (186-190)) , 1994 .

[47]  N. Copeland,et al.  The IRS-2 gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. , 1997, Molecular endocrinology.

[48]  T. Forst,et al.  Bone Mineral Density and Bone Metabolism in Diabetes Mellitus , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[49]  E. Kondo,et al.  Association of insulin receptor substrate proteins with Bcl-2 and their effects on its phosphorylation and antiapoptotic function. , 2000, Molecular biology of the cell.

[50]  J. Zerwekh,et al.  Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[52]  Y. Yazaki,et al.  Signal transduction mechanism of insulin and insulin-like growth factor-1. , 1996, Endocrine journal.

[53]  S. Mohan,et al.  Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. , 1994, The Journal of clinical endocrinology and metabolism.

[54]  T. Hirano,et al.  Signaling through Gp130: toward a general scenario of cytokine action. , 1999, Growth factors.